Page last updated: 2024-10-28

hydroxychloroquine and Heart Defects, Congenital

hydroxychloroquine has been researched along with Heart Defects, Congenital in 2 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Lewis, MJ1
Anderson, BR1
Fremed, M1
Argenio, M1
Krishnan, U1
Weller, R1
Levasseur, S1
Sommer, R1
Lytrivi, ID1
Bacha, EA1
Vincent, J1
Chung, WK1
Rosenzweig, EB1
Starc, TJ1
Rosenbaum, M1
Pisoni, CN1
Brucato, A1
Ruffatti, A1
Espinosa, G1
Cervera, R1
Belmonte-Serrano, M1
Sánchez-Román, J1
García-Hernández, FG1
Tincani, A1
Bertero, MT1
Doria, A1
Hughes, GR1
Khamashta, MA1

Other Studies

2 other studies available for hydroxychloroquine and Heart Defects, Congenital

ArticleYear
Impact of Coronavirus Disease 2019 (COVID-19) on Patients With Congenital Heart Disease Across the Lifespan: The Experience of an Academic Congenital Heart Disease Center in New York City.
    Journal of the American Heart Association, 2020, Volume: 9, Issue:23

    Topics: Academic Medical Centers; Adult; Aged; Azithromycin; Cohort Studies; COVID-19; Female; Genetic Disea

2020
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.
    Arthritis and rheumatism, 2010, Volume: 62, Issue:4

    Topics: Autoantigens; Dexamethasone; Drug Therapy, Combination; Female; Heart Block; Heart Defects, Congenit

2010